Document is current

Article History

Received: 28 January 2019

Accepted: 20 September 2019

First Online: 25 October 2019

Competing interests

: B.A.P.; Research Funding: Pfizer, Novartis, Glaxo Smith Kline, Genentech/Roche, Breast Cancer Research Foundation, Safeway Foundation to the Athena Breast Health Network, University of California Office of the President to the Athena Breast Health Network, and Patient Center Outcomes Institute (PCORI)–National Institutes of Health. Travel/honoraria past 3 years: NCCN Board Meetings/Annual Meeting, Alliance Clinical Trials Group semiannual meetings, and Athena Breast Health Network semiannual meetings—University of California consortium. Spouse: Bioalta Inc. consulting, EMD Serona consulting and travel, and Salk Institute licensing fees for technique involving protein-interaction technology, Merck (Incorporated stock). T.J.K. Cirmtuzumab was developed by T.J.K. and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock/options to the university and T.J.K. <i>Research Funding to T.J.K</i>.: Pharmacyclics/AbbVie, Breast Cancer Research Foundation, Oncternal Therapeutics, Inc., California Institute for Regenerative Medicine (CIRM), R01-CA236361 from the National Cancer Institute/NIH, and Research Agreement—VelosBio, Inc., Celgene. <i>Travel/Honoraria 2017–2019 (T.J.K.)</i>: Pharmacyclics/AbbVie, Genentech/Roche, Janssen, Gilead, National Cancer Institute/NIH, Celgene, Indy Heme Review, University of Nebraska Medical Center/Research to Practice, Society of Hematologic Oncology, Shenzhen Cancer Center, European Research Initiative on CLL (ERIC), Dava Oncology, Patient Power (LLC), Breast Cancer Research Foundation, German CLL Study Group (GCLLSG), iwNHL, NCCN CLL/SLL Hairy Cell Leukemia Panel Meeting, TG Therapeutics, Verastem, Bionest Partners, and OncLive. The remaining authors declare no competing interests.